Epidemiological studies regarding Alzheimer's disease (AD) in smokers currently suggest
inconsistent results. The clinicopathological findings also vary as to how AD pathology is …

Cholinergic dysfunction is one of the cornerstones of Alzheimer's disease (AD) pathology.
Reviewed here is evidence evaluating relationships between smoking, nicotine exposure …

Activation of neuronal nicotinic acetylcholine receptors (nAChRs) has been shown to
maintain cognitive function following aging or the development of dementia. Nicotine and …

Nicotinic cholinoceptive dysfunction associated with cognitive impairment is a leading
neurochemical feature of Alzheimer's disease. There-fore, nicotinic acetylcholine receptors …

Receptor binding studies have uniform-ly found a significant reduction in the density of
neuronal nicotinic cholinergic receptors in postmortem tissue obtained from Alzheimer's …

Nicotinic cholinergic agonists represent a relatively newly developing area for therapeutic
intervention in Alzheimer disease (AD) and related neurodegenerative dementias. Loss of …

The two hallmark lesions of Alzheimer's disease (AD) are extracellular amyloid plaques,
mainly formed by a small peptide called amyloid-β (Aβ), and neurofibrillary tangles, which …

The association between nicotinic acetylcholine receptor (nAChR) dysfunction and cognitive
decline in Alzheimer's disease (AD) has been widely exploited for its therapeutic potential …

Over the past decade, researchers have established a definite relationship between
Alzheimer's disease and nicotinic acetylcholine receptors (nAChRs). Not only do cholinergic …

Increases in neuronal nicotinic receptors (nAChRs) in response to nicotine exposure have
been reported in cell cultures, rodent brains, and in the brains of human smokers. The …